Rating: Neutral | Target Price: RMB 40-45 | Current Price: RMB 39.84 (close, 2026-10-27) | Margin of Safety: approx. +0.4% (base-case fair-value floor of RMB 40) | Time Horizon: 12 months
Kelun Pharmaceutical's market cap of RMB 63.377 billion (RMB 39.84 × 1.59078 billion shares) is essentially identical to the sum of its 56.44% stake in Kelun-Biotech (approx. RMB 52.7-56.4 billion) plus its 72.19% stake in Chuanning Biotech (approx. RMB 11.6 billion) — the market is effectively treating Kelun as a discounted holding vehicle for Biotech's ADC assets, with the implied valuation of the traditional IV-fluids + generics cash-cow business (FY2025 non-GAAP net profit RMB 1.597 billion) approaching zero under a zero-discount framework. This structure is not a static margin of safety: Biotech's market cap itself embeds high expectations (the bulk of 2026H1 profit is one-off settlement income; the core business remains loss-making once excluded), and the holding-company discount lacks a convergence mechanism. The traditional business remains in a downtrend driven by centralized procurement and the antibiotic-intermediates price cycle (2026H1 non-GAAP -29.03%), though the decline is narrowing, and the extremely low 2025Q3 base makes single-quarter improvement in the Q3 report highly likely. The SOTP base-case fair value of RMB 40-45 largely overlaps the current price; probability-weighted fair value is approx. RMB 39.7, with symmetric risk-reward (bear -30%~-40% / bull +26%~+41%) and no effective margin of safety. Over the next 12 months, the key is the event-verification chain: the 10-29 Q3 report (whether the non-GAAP decline narrows to within -20%) → sac-TMT first-line indication approval (2026Q4-2027Q1) → first FDA BLA (PDUFA 2027-06-15).
This report characterizes the opportunity structure as event-verification-driven rather than statically undervalued (evidence grade B, neutral market environment):
Key evidence:
FY2025 IV-fluids volume was 3.986 billion bottles/bags (-8.31%), revenue RMB 7.484 billion (-16.02%), gross margin 55.51% (-4.65pp), with the company explicitly citing "counter-cyclical measures to defend market share amid industry demand decline"; Chuanning Biotech FY2025 net profit was RMB 768 million (-45.13%). Two boundary notes: first, the slope of decline is narrowing — 2026Q1 non-GAAP -32.4%, Q2 narrowing to approx. -24.5%, and with the 2025Q3 single-quarter non-GAAP base of only RMB 161 million, single-quarter YoY improvement in 2026Q3 is highly likely; second, the settlement agreement is not purely a one-off termination — it includes royalty clauses for out-licensing of pipeline assets such as YL201, and some follow-on royalties in 2027 may partially hedge the cliff, but neither magnitude nor timing can be relied upon. If government grants fade (zeroing out the non-recurring RMB 237 million would drag total profit by approx. 10%) and the settlement income disappears, 2027 headline profit faces base-effect pressure.
Key evidence:
Three points of clarity on this structure are essential: First, "implied valuation of zero" holds only in a frictionless zero-discount world; at a conventional holding discount, the core business is priced at 5.6-11.5x, comparable to procurement-pressured IV-fluids peers (China Resources Double-Crane 10.4x, Chenxin Pharma 13.1x) — not free. Second, the anchor itself carries risk — Biotech's TTM P/E runs to several hundred times, and 2026H1 profit is mostly one-off settlement income; if Biotech's market cap contains a bubble, Kelun's "discount" is merely a mirror image of subsidiary overvaluation rather than parent-company undervaluation. Third, monetizing the 56.44% controlling stake at market prices means losing control and triggering approx. 25% transfer income tax; a structural discount of an A-share parent to its listed subsidiary without a convergence mechanism is the norm. The correct reading of this structure is therefore: buying Kelun is roughly equivalent to buying a leveraged reflection of Biotech (amplifying its ups and downs), plus a traditional business priced at a low peer multiple — it defines the source of stock-price elasticity but does not constitute an arbitrage.
Key evidence:
The ramp is real: 4 indications approved in China (first 2 already in NRDL), covering 30 provinces and 1,200+ hospitals. But the quality of profit inflection deserves a discount: of Biotech's 2026H1 profit of RMB 388 million, the MediLink settlement contributed RMB 703 million — excluding it, the core business remains loss-making by roughly RMB 300 million; in 2027, without settlement income, Biotech's consolidation could swing from an increment back to a drag. On the competitive landscape, Daiichi Sankyo's Datroway was approved in the US ahead of sac-TMT for 1L TNBC and later-line HR+/HER2- breast cancer, Gilead's Trodelvy received broad FDA approval in 1L TNBC in June 2026, and TROPION-Lung08 (Dato-DXd + pembrolizumab) is racing in parallel for 1L NSCLC — sac-TMT is a chaser, not a first mover, in US/EU first-line settings. On milestones, under the Merck partnership sac-TMT's own milestone cap is approx. USD 1.363 billion (per the 2022 agreement terms); "approx. USD 1.1 billion remaining" is management's figure with a precedent of shrinkage (SKB315 was returned to Merck with global rights retained and no refund required); overseas sales royalties (management's "mid-single-digit to low-double-digit" percentage) will only begin generating revenue after approvals in 2027. Conclusion: the option is real and the data are solid (multiple Phase III endpoints met), but the path to monetization carries three layers of uncertainty — regulatory, competitive, and commercial.
Key evidence:
The cycle-bottom judgment holds (Chuanning's P/B at its historical lowest percentile, corroborated by Fosun Pharma's comparable metrics), but the "reversal confirmed" evidence is insufficient: the price increase is so far only a single-week quote, not yet reaching the trend threshold of "holding above RMB 200/kg for 4 consecutive weeks," and the Indian anti-dumping investigation is an unpriced downside variable for export volumes. Elasticity estimates must remain restrained: restoring Chuanning's net profit from approx. RMB 390 million in 2026 (annualized) to a mid-cycle RMB 850 million would add approx. RMB 330 million to Kelun's attributable profit, implying market-cap elasticity of approx. 6% at 12x — a bonus, not a dominant variable. Also note the unlock of Kelun's 1.610 billion Chuanning shares on 2026-12-28 (not a selling pressure per se, but it changes the free-float structure).
| Metric | FY2023 | FY2024 | FY2025 | 2026H1 | 2026Q1 |
|---|---|---|---|---|---|
| Revenue (RMB 100M) | 214.54 | 218.12 | 185.13 | 88.39 | 42.59 |
| Attributable net profit (RMB 100M) | 24.56 | 29.36 | 17.02 | 11.28 | 4.54 |
| Non-GAAP attributable net profit (RMB 100M) | 23.66 | 29.02 | 15.97 | 6.99 | 3.81 |
| Gross margin | 52.43% | 51.69% | 47.85% | 47.57% | 45.31% |
| Attributable net margin | 11.45% | 13.46% | 9.19% | 12.76% | 10.65% |
| Operating cash flow (RMB 100M) | 53.37 | 44.93 | 26.42 | 23.41 | — |
| Free cash flow (RMB 100M, OCF - CapEx) | 35.68 | 28.15 | 10.20 | 16.67 | — |
| Cash + trading financial assets (RMB 100M) | 63.67 | 58.95 | 74.89 | 94.99 | — |
| Interest-bearing debt (RMB 100M) | 71.39 | 42.07 | 35.04 | 44.18 | — |
| Debt-to-asset ratio | 36.87% | 28.35% | 26.46% | 28.11% | — |
| Cash dividend payout ratio | 51.82% | 41.34% | 55.51% | — | — |
Note: Balance-sheet stock items (cash-like assets RMB 9.499 billion, interest-bearing debt RMB 4.418 billion, net cash RMB 5.081 billion) are all on a consolidated basis as of 2026-06-30; cash-like assets = cash of RMB 6.158 billion + trading financial assets of RMB 3.342 billion (excluding restricted cash; consistent basis across both periods).
Reasons for metric changes (items with YoY ≥ ±20%):
2026H1 revenue was RMB 8.839 billion (-2.70%), with the decline narrowing markedly from FY2025's full year (-15.13%); attributable net profit was RMB 1.128 billion (+12.71%) and non-GAAP RMB 699 million (-29.03%) — headline growth and core profitability are moving in completely opposite directions, with the RMB 428 million gap almost entirely attributable to the MediLink settlement received by Biotech (cash of RMB 703 million, of which approx. RMB 326 million goes to Biotech's minority shareholders). Gross margin was 47.57% (-2.19pp), continuing the transmission of procurement price cuts; by driver, the company stated: "Kelun-Biotech's innovative-drug sales revenue increased and settlement income was received, lifting profit YoY; IV and non-IV formulations saw prices decline under centralized procurement, reducing profit YoY; some Chuanning product prices declined, reducing profit YoY." Expenses were consistent with management's comments in late-August investor communications: R&D expense RMB 1.213 billion (+15.69%, "innovative-drug R&D spend will increase step by step as clinical programs advance"), selling expense +8.04% (innovative-drug commercialization investment phase), administrative expense -10.87%. Operating cash flow was RMB 2.341 billion (+96.81%), including settlement cash; excluding it, cash collection quality remains solid (OCF/attributable profit approx. 1.4-1.5x). Dual-chamber bags (powder-liquid) are in short supply with capacity ramping; management is "confident in effective production and sales growth next year." The market has not yet formed a consensus anchor on single quarters, and this report makes no beat-or-miss judgment; directionally, however, 2026H2 is the first full half-year after the Sichuan alliance (executed end-March) and Guangdong ten-province alliance procurement price cuts, with no settlement-income hedge — the true stress test window for full-year earnings. The 10-29 Q3 report's single-quarter non-GAAP profit (vs. the 2025Q3 base of RMB 161 million) will be the first verification point.
Business model: An asset-heavy pharmaceutical group with a "one body, three wings" structure — large-volume IV fluids (global volume leader, 3.986 billion bottles/bags, 40.4% of revenue, 55.51% gross margin) + generic formulations (a procurement-driven share game) + antibiotic intermediates (Chuanning Biotech, a bio-fermentation cyclical, 24.9% of revenue, 29.25% gross margin) + innovative ADC drugs (Kelun-Biotech, 11.1% of revenue, 72.35% gross margin, not yet genuinely profitable). Three listed platforms (Kelun A-share, Chuanning ChiNext, Biotech HK). Revenue has no subscription-like attributes; pricing power exists only in innovative drugs (NRDL negotiations trading volume for price) and differentiated new IV products (dual-chamber/triple-chamber bags in short supply); pricing power in basic IV fluids and generics has been fully ceded to centralized procurement.
Cash content of earnings: OCF/attributable net profit was 2.17 → 1.53 → 1.55 → 2.08 across FY2023-2026H1 (2026H1 includes settlement cash; excluding it, approx. 1.4-1.5x) — book profit has consistently converted fully into operating cash; collection quality is a strength of this case. FCF/attributable profit was 1.45 → 0.96 → 0.60: the FY2025 decline to 0.60 touched the warning zone, mainly due to still-high capex of RMB 1.622 billion (CapEx/D&A at 1.14x, investment intensity converging) plus a shrinking profit base, rather than receivables build-up (receivables of RMB 4.673 billion, essentially flat YoY). Recurring earnings must be viewed excluding non-recurring items: the FY2025 gap between attributable and non-GAAP profit was RMB 105 million (mainly government grants); in 2026H1 it was RMB 428 million (settlement income) — extrapolating from the attributable figure would overstate the true earnings center by approx. 20%-40%.
Return on capital: FY2025 consolidated ROIC approx. 5.8%, below the cost of equity (approx. 9.5%). But this figure is depressed by two things: book equity includes RMB 5.081 billion of net cash, and Biotech's approx. RMB 2.2 billion of R&D spend is fully expensed (R&D capitalization rate 0%, no accounting adjustment room — a conservative basis). By layer, the traditional IV + formulation business has a 49.6% gross margin and strong cash collections; the core business's returns are not poor. The "below cost of capital" at the consolidated level is essentially the current-period cost paid for the ADC option.
Capex quality: CapEx/D&A 1.29x (FY2024) → 1.14x (FY2025), construction in progress of RMB 1.504 billion; IV-fluids consolidation production lines have come on stream — investment intensity is converging toward maintenance levels; no maintenance/growth split has been disclosed.
Red flags: 2026H1 attributable profit growth is entirely dependent on one-off gains (high); government grants of RMB 577 million across both bases equal 24% of FY2025 total profit (medium); annual external donations of approx. RMB 200 million with undisclosed beneficiaries (low); low customer concentration (top five at 21.7%).
Consistency between words and deeds: partially delivered, with a preference for qualitative statements. The company does not provide quantitative performance guidance, and the annual report outlook is primarily qualitative in direction. The 2024 annual report had qualitatively anticipated "increasing Bota's overseas licensing revenue and continued growth in antibiotic intermediates," but in FY2025 actual licensing and milestone revenue fell -20.14% and intermediates fell -23.20%—the directional statements did not materialize, though this was due to the industry price cycle rather than a breach of commitment. Cost-side commitments were initially delivered: IR promised "stable and slightly lower administrative expenses, strict control of generics R&D expenses," and in 2026H1 administrative expenses fell -10.87%, fulfilling that promise; selling expenses rose +8.04%, consistent with its stated "innovative drug sales investment period." During the industry compliance rectification from May to July 2025, the company proactively disclosed that "in-hospital compliant promotion began in July, and product sales have basically recovered to April levels"—a candid disclosure.
Shareholder friendliness: genuine dividends coexist with dilution; overall neutral to friendly. The dividend payout commitment (40%-60% per year under the three-year plan) has been delivered for three consecutive years: 51.82% → 41.34% → 55.51% (FY2025 dividend of RMB 945 million; dividend yield of approximately 1.5% at the current share price), with both interim and annual dividends; two buyback rounds canceled a combined 3.44 million shares, and 7.27 million additional shares were canceled in 2026H1 (total share capital reduced to 1,590.78 million shares). But dilution has also continued: Kelun convertible bonds diluted the share base by approximately 6.8% through conversions from 2022-2024; Bota's two H-share placements (net proceeds of RMB 1.778 billion in 2025-06 and HKD 2.723 billion in 2026-07) reduced Kelun's stake from 57.50% to 56.44% with further dilution to come; the 2026 buyback cap of RMB 34.41 is below the current price, so buybacks cannot scale up in the short term.
Risk signals: Controlling shareholder Liu Suige holds 23.83% of shares, with 91.287 million shares pledged (24.1% of his holdings; company-wide pledge ratio of 7.32%), and rolling pledges/releases continued through August-September (personal funding needs); the second-largest shareholder, Yaan SOE, has seen its stake reduced to 5.90%—about 0.9 percentage points above the 5% disclosure threshold—and once it falls below 5%, further reductions will no longer be visible; annual donations of approximately RMB 200 million with undisclosed beneficiaries.
| Segment (FY2025, pre-elimination) | Revenue (RMB 100M) | Share | Gross Margin | Revenue YoY | One-Line Business Logic |
|---|---|---|---|---|---|
| IV solutions + formulations + distribution (other business segment) | 12,147 | 65.6% | 49.56% | IV solutions -16.0% / non-IV formulations -3.2% | Scale + cost + market access in the era of centralized procurement; structural upgrade to dual-chamber/triple-chamber bags |
| Chuanning Biotech (antibiotic intermediates, 72.19% stake) | 4,616 | 24.9% | 29.25% | -19.8% (net profit -45.1%) | Fermentation-based cyclical commodity leveraging Xinjiang's energy endowment; among global output leaders |
| Kelun-Biotech (innovative ADC drugs, 56.44% stake) | 2,058 | 11.1% | 72.35% | +6.5% (net loss of RMB 382 million) | sac-TMT licensed globally to Merck + domestic commercialization ramp; high margin, high investment |
Product-level supplement: IV solutions RMB 7.484 billion (40.4%, gross margin 55.51%), non-IV RMB 8.867 billion (47.9%, 40.78%, of which formulations 4.036 billion / intermediates and APIs 4.497 billion), R&D projects and licensing RMB 1.513 billion (8.2%, 64.94%, heavily one-off in nature, mainly Merck-related).
Profit drivers: Estimated by "revenue × gross margin"—IV solutions + formulations contributed approximately RMB 6.02 billion of gross profit (68.0% of segment gross profit), Bota approximately RMB 1.49 billion (16.8%), and Chuanning approximately RMB 1.35 billion (15.2%). The largest segment by revenue, IV solutions + formulations, is also the absolute profit mainstay; Bota contributes 16.8% of gross profit (72.35% gross margin) with only 11.1% of revenue, but this is consumed by R&D expenses; Chuanning is the main source of profit volatility (net profit 1.40 → 768 million → annualized approximately 390 million RMB, shrinking more than 70% over two and a half years). The gross margin structure gap is 43pp (Bota 72.35% vs. Chuanning 29.25%): the former sells clinical data and global rights, the latter sells fermentation capacity as a commodity—two completely different businesses within the same group, and the consolidated statements obscure this stratification.
Accounting red flags:
Cross-period consistency:
Current market data (closing price RMB 39.84, 2026-10-27): Market cap of RMB 63.377 billion; PE(TTM) 34.65x (percentiles over the last 1/3/5 years: 59%/86%/92%)—but TTM earnings include RMB 428 million in one-off gains, plus Bota's losses and Chuanning's cyclical trough; the PE percentile is not representative and is for reference only; PE(TTM) excluding one-offs is approximately 48.3x; PB 2.57x (76th percentile over the past 5 years); dividend yield approximately 1.49%. Forward metrics: consensus FY2026E EPS of RMB 1.26 implies 31.6x, PEG 1.72 (for a segment structure containing an ADC option, the linear PEG assumption is distorted; for cross-validation only).
| Peer | PE(TTM) | PB | FY2025 Net Profit Growth | ROE | Positioning |
|---|---|---|---|---|---|
| Kelun Pharmaceutical | 34.65 (~48.3 ex-one-offs) | 2.57 | -42.0% (ex-one-off -45.0%) | 7.2% (weighted) | IV solutions leader + ADC option |
| China Resources Double-Crane (600062) | 10.4 | 1.37 | +5.8% | 14.9% | Third in IV solutions, no innovative pipeline |
| Sichuan Renhe Group (2005.HK) | 15.0 | 0.98 | -55.6% | 6.5% | Second in IV solutions, more pain from centralized procurement pass-through |
| Chenxin Pharmaceutical (603367) | 13.1 | 0.94 | -17.2% | 6.9% | Second-tier IV solutions, option-free comparison |
| Federal Pharmaceutical (3933.HK) | 21.3 | 0.67 | -21.6% | 13.1% | Intermediates + insulin + GLP-1 |
Market-Implied Expectations: SOTP reverse-engineering—the current RMB 63.377 billion market cap ≈ Bota's equity value (52.7-56.4 billion RMB) + Chuanning's equity value (~11.6 billion RMB) combined, implying a negative RMB 460 million to RMB 90 million valuation for the traditional core business at zero discount; applying a 20%-30% holding discount implies 5.6-11.5x PE for the core business, comparable to procurement-pressured peers (Double-Crane at 10.4x). In other words, the current price requires the market to believe: Bota's HK-listed market value is roughly fair + the traditional core business is priced at a low peer multiple—this is not a mispricing, but a migration in the focus of valuation. The implied-expectation pressure on the other side: consensus FY2026 net profit attributable to parent of RMB 2.004 billion requires approximately RMB 876 million in 2026H2 with no settlement payment as a hedge, while H2 is the first full half-year of procurement-driven price cuts and Chuanning's Q3 standalone net profit fell -65.4%—earnings expectations have 3%-13% downside revision room (this report's own estimate: RMB 1.75-1.95 billion).
Three-Tier Value (EPV): Measured by sustainable equity cash flows (parent's traditional core business RMB 1.5 billion + Chuanning mid-cycle RMB 850 million × 72.19% ≈ 610 million RMB + Bota at a neutral 0, total sustainable FCFE of approximately RMB 2.11 billion, RMB 1.33 per share, cost of equity 9.5%), EPV-zero growth is approximately RMB 13.99/share (range 10.6-15.7)—the residual of the current price relative to EPV is approximately RMB 25.85, or 65% of the current price, but the bulk of that residual is not narrative; it is the observable market-value mapping of the 56.44% stake in Bota (backed by multiple Phase III OS/PFS hard data readouts); asset value (the two listed equity stakes converted at market value) is approximately RMB 39.97/share, almost exactly equal to the current price. The current price is neither "the market paying only for zero growth" nor a bubble—it is almost precisely equal to the asset tier, with everything above EPV bet on ADC delivery.
Three Scenarios and Odds (12 months):
| Scenario | Probability | Fair Range | vs. Current Price | Swing Factor |
|---|---|---|---|---|
| Bear | 30% | RMB 24-28 | -39.8% ~ -29.7% | Bota drawdown of 40% (FDA setback / 1L approval slip / competitive squeeze) + core business down another 15% + Chuanning double-dip |
| Base | 50% | RMB 40-45 | +0.4% ~ +13.0% | Q3 ex-one-off decline narrows to within -20%, Bota flat to slightly up (75% discount), Chuanning PB modest recovery |
| Bull | 20% | RMB 50-56 | +25.5% ~ +40.6% | 1L NSCLC approval + positive TroFuse re-readout + discount compresses to 20% (aligned with the top sell-side range of RMB 51-61) |
Probability-weighted fair value is approximately RMB 39.65, essentially overlapping with the current price of RMB 39.84—symmetrical odds with no effective margin of safety (the base-case fair floor of RMB 40 implies a safety margin of only +0.4%). The bear case is independently constructed on a stress assumption of a 40% drawdown in Bota's market cap; external comparison coordinates: the lowest sell-side target price is RMB 36.96 (-7.2% vs. current, based on the FY2026E attributable net profit floor of RMB 1.912 billion; no sample covers a "major Bota drawdown transmission" scenario), the highest RMB 61 (n=7), median RMB 46.4—sell-side floors are far above this report's bear case; the difference stems from the bear case's independent stress test of the SOTP primary weight (Bota at 55%-60%), and sell-side floors are not adopted as bear-case boundaries. The bull case is close to the iFinD high of RMB 51.10. Base-case exit multiple anchors: 11x ex-one-off earnings for the traditional core business (vs. Double-Crane at 10.4x and its own post-procurement earnings midpoint), a 25% holding-discount midpoint (vs. the typical 20%-30% range for A-share parent-subsidiary structures).
Own Earnings Forecast (Reconciliation Anchor): FY2026 revenue RMB 17.7-18.7 billion (-4%~+1%), attributable net profit RMB 1.75-1.95 billion, ex-one-off RMB 1.25-1.40 billion; FY2027 revenue RMB 18.5-20.0 billion (+3%~+7%), attributable net profit RMB 2.0-2.4 billion, ex-one-off RMB 1.5-1.7 billion. Management provides no quantitative guidance (the dividend payout commitment of 40%-60% is the only hard guidance); this forecast is 3%-13% below consensus, mainly due to Chuanning's accelerating Q3 deterioration and no settlement payment hedge in H2.
Conclusion: Fairly Priced (fair). Quality and price are best described in tiers: the traditional business is a cash cow structurally suppressed by centralized procurement (all peers sit at decade-low valuation percentiles), Bota is a commercialized, hard-data-backed global-class ADC asset (though its profitability turnaround includes one-offs), and Chuanning is at a cyclical trough. The current price essentially fairly prices the three-tier combination of "assets + earnings + options"—neither overextended nor discounted—buying Kelun is effectively accepting Bota's leveraged market-value mapping and its drawdown risk; the current price offers no downside protection. Target price RMB 40-45 (base case).
Industry Space. Kelun spans three tracks of vastly different scale and growth. Large-volume IV solutions: China consumed approximately 10.6 billion bottles/bags in 2023 (per Huajing Industry Research Institute), worth approximately RMB 35-40 billion (third-party industry estimate; reliability to be verified); volume growth has been structurally suppressed long-term by "antibiotic restriction + rational drug use" policies and is near a natural steady state, with value-side expected to grow low-single-digits or stay flat under procurement; the global IV solutions market is approximately USD 14.8 billion in 2025, with a 2026-2035E CAGR of approximately 8.2% (driven by volume growth and structural upgrade). Antibiotic intermediates: globally priced fermentation-based commodities, at a five-year price cycle trough in 2025 (erythromycin thiocyanate / 6-APA / penicillin industrial salt prices declining), with marginal rebalancing in 2026—6-APA export quotes recovered from the 2025 trough of RMB 185/kg to RMB 210-220/kg by April 2026; India's minimum import price (6-APA at approximately RMB 272/kg equivalent) forms an upside anchor, but India's anti-dumping investigation into Chinese penicillin industrial salt on 2026-09-28 adds new export uncertainty. ADC (antibody-drug conjugates): the global market grew from approximately USD 2.8 billion in 2019 → approximately USD 18.7 billion in 2025 (6.7x over six years, CAGR 37.2%) → approximately USD 94 billion by 2032E (Frost & Sullivan, CAGR approximately 25.9%); the Chinese market from approximately RMB 15.9 billion in 2026E → approximately RMB 66.2 billion by 2030E (CAGR approximately 42.8%). The core of Kelun's valuation narrative has migrated from IV solutions to ADC.
Industry Chain and Value Distribution. The chain runs "fermentation inputs (corn/molasses/energy) → intermediates → APIs → formulations → hospital/insurer payment"; ADC has a separate chain of "antibody-linker-payload conjugation platform → global clinical development → licensing to multinationals / self-commercialization." Kelun is the industry's most complete "intermediates-APIs-formulations-innovative drugs" integrated player: upstream, it locks in costs via scale and Xinjiang's low electricity prices (strong bargaining power over packaging materials/raw materials, with partial self-supply of packaging); downstream, it faces the National Medical Insurance as a monopsony buyer—basic IV solutions and generics are price takers (some winning bid prices are already below bottled water; non-standard plastic bottles are at breakeven), while innovative drugs gain rapid access through NRDL negotiations (trading price for volume; sac-TMT entered the NRDL in its approval year, dual-channel in 30 provinces, 1,200+ hospitals, 400+ DTP pharmacies); overseas, its licensing to Merck (USD 175 million upfront + milestone pool capped above USD 9 billion, cumulative cash received of USD 729 million, mid-single-digit to low-double-digit royalties) is one of the most successful overseas expansion templates among Chinese pharma companies. Gross profit is retained at both ends: upstream Chuanning earns cyclical profits, downstream Bota earns an innovation premium, while basic IV solutions in the middle are compressed to near cost by procurement—this is precisely the industry logic that "value increments lie in ADC and high-barrier IV solutions" (triple-chamber bag sales +30.9%, dual-chamber bags +39.4%).
Supply-Demand and Competitive Structure. IV solutions: demand = inpatient admissions × per-capita infusion volume; volume steady-state, structure upgrading (soft bags/upright bags priced 2-3x plastic bottles); on the supply side, capacity is concentrating among leaders, with over 60% of the national IV solutions market already under volume-based linkage/procurement (Sichuan alliance effective 2026-03-31, Guangdong ten-province alliance renewal, 14 provinces/regions in total), accelerating the exit of small and mid-sized capacity; in terms of competitive structure, Kelun held approximately 41.4% volume share in 2023 (third-party aggregate estimate, to be verified) and Sichuan Renhe approximately 18.1%, with CR3 approximately 70%+; during the 2025 procurement execution period, Kelun's share rose against the trend (its own volume -8.3% but the industry exiting faster; Sichuan Renhe volume -24.5%). Intermediates: domestic oversupply in a clearing phase; Chuanning ranks among the global leaders in erythromycin thiocyanate / cephalosporin / penicillin intermediate output, forming a duopoly pricing interaction with Federal Pharmaceutical (linked 6-APA quoting). ADC/TROP2: only 3 TROP2 products are approved globally—Gilead's Trodelvy (USD 1.4 billion sales in 2025, accelerating in 2026), Daiichi Sankyo/AstraZeneca's Datroway (US approval in 2025-01, first-mover in 1L TNBC), and Kelun-Biotech's sac-TMT (the first TROP2 ADC approved for a lung cancer indication globally); entry barriers are conjugation platforms + clinical data assets + multinational BD channels—over ten domestic developers exist, but only Bota has achieved lung cancer approval + a global Phase III matrix (18 Merck programs). The competitive frontier has shifted from later lines to first-line: sac-TMT's Lung05/Lung06 (dual-population 1L NSCLC) races head-to-head with TROPION-Lung08, and in 1L breast cancer it faces the first-mover advantage of Datroway/Trodelvy—Bota is leveraging the world's most complete Phase III matrix and a Keytruda combination strategy to achieve a late-mover advantage, but this is precisely the source of the competitive risk described in Thesis Three.
Cycles and Regulation. IV solutions are in the "later stage of procurement clearing": the eleventh national procurement round opened bids in 2025-10 (55 products, average price cuts roughly flat with the tenth round's 58%), execution in February 2026, with rules shifting toward "anti-low-price involution" (1.8x anchor price constraint, supply-security and quality clauses)—the floor for legacy profits is becoming visible, but the next renewal round remains a continuing stress test for the IV cash cow. Antibiotic intermediates are on the "eve of recovery from the cycle trough": leading indicators are weekly 6-APA/erythromycin thiocyanate quotes (currently raised quotes in late October, not yet at trend-confirmation threshold) and the progress of India's anti-dumping investigation. ADC is in the "early-to-mid growth phase": NRDL negotiation timing was brought forward in 2026 (on-site negotiations in September, list release by end of November), with the first-ever pathway from "commercial insurance innovative drug list to NRDL"; if sac-TMT's new indications enter the 2026 list, it will directly steepen the 2027 volume ramp; the US BIOSECURE Act provides a roughly five-year safe harbor, with limited direct impact on licensing-based overseas expansion (the Kelun-Merck model).
Company Industry Positioning: Absolute IV solutions leader (rising share), global top-tier in intermediates (stable share), and domestic #1 in TROP2 ADC (per SPDB International and others, in a domestic leading window). Empirical evidence of the integration moat: under the same procurement shock, Kelun's FY2025 ex-one-off profit fell -45.0%, while second-tier IV peer Chenxin fell -39.8%, Sichuan Renhe's net profit fell -55.6%, and Huaren slipped into losses—Kelun maintained profit resilience (attributable net profit of RMB 1.702 billion, still the largest in the sector) through ADC contribution and cost integration, and is the only one of the three with a global-class innovative pipeline.
Conclusion: Neutral (confidence 0.58, 12 months). The current price of RMB 39.84 largely overlaps with the base-case fair value of RMB 40–45; probability-weighted fair value is approximately RMB 39.65, with a safety margin of only +0.4%—symmetric odds. For existing holders, the rationale to hold is valid (dense approval catalysts, Chuan Ning's cyclical elasticity, dividend support); for those not yet positioned, the current price does not offer an attractive entry point—it is better to wait for two types of reassessment points: a pullback to around RMB 34 (where the core business's implied valuation compresses and odds turn asymmetric), or a re-rating based on new information after the Q3 earnings report / approval events. The essence of holding this stock is accepting the leverage to Botai: if Botai rises 30%, Kelun most likely gaps up; if Botai falls 30%, Kelun has no buffer—the 55%-60% SOTP weight determines this.
Risk and catalyst calendar:
Monitoring points (by importance): ① Q3 report (Oct 29) quarterly non-GAAP net profit (≥ RMB 220 million confirms stabilization; < RMB 161 million triggers downward revision of earnings expectations); ② 6990.HK share price (a fall below HKD 400 signals loss of the Botai anchor); ③ approval timeline for sac-TMT's two 1L indications (if not approved before 2027Q1, the catalyst thesis is deferred); ④ FDA BLA review (a CRL is the bear-case trigger); ⑤ weekly 6-APA/penicillin industrial salt price quotes (holding above RMB 200/kg for 4 consecutive weeks confirms a cyclical upturn); ⑥ IV-fluid centralized procurement renewal documents, whether Ya'an SOE's stake falls below 5%, and whether the controlling shareholder's pledge ratio exceeds 10%; ⑦ FY2026 annual dividend in March–April 2027 (degree of fulfillment at the lower bound of the 40%-60% commitment).
This report is based on public information and company disclosure documents; price anchors are closing prices as of 2026-10-27. Forward-looking estimates herein are scenario analyses and do not constitute investment advice.